ClinicalTrials.gg
DrugBiologicalRead study by study

Tremelimumab clinical trials

Also written CP-675,206, Ticilimumab, CP-675206 and Imjudo.

studies test it
221
open now
28
in phase 3
21
first study started
2003
ClinicalTrials.gov finds 278 studies for tremelimumab. How that becomes 221 here

Every study that search finds has been read, to see whether and how it gives tremelimumab. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 278Found by its intervention search · See all 278 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 244 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −3
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  4. 276Give tremelimumab to participants
  5. −15Observe patients on it, or give it outside a trial
  6. −1Compare another treatment with it
  7. −39Give it beside what is tested
  8. 221Test it: the count on this site

Get an email when these change. Save the tremelimumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Oct 2022 · IMJUDO · BLA 761289 (FDA, Drugs@FDA)
European Union
20 Feb 2023 · Tremelimumab AstraZeneca · EMEA/H/C/004650 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tremelimumab
155
Anti-CTLA4 Human Monoclonal Antibody CP-675,206
23
anti-CTLA4 human monoclonal antibody
3
Treme
2
Tremelimumab-actl
2

Brand

Imjudo
8

Development codes

CP-675,206
49
CP-675206
21
MEDI1123
2

Other names

Ticilimumab
26

In one entry with another drug

Given together, or one or the other

Durvalumab + Tremelimumab
4
MEDI4736 + Tremelimumab
3
Durvalumab,Tremelimumab
2
MEDI4736+Tremelimumab
2

Studies by the year they started

221 studies that test it; most in 2017 (37)

Studies that test tremelimumab, by start year
YearStudies
20031
20041
20051
20066
20074
20083
20093
20102
20122
20135
20147
201515
201627
201737
201835
201916
202012
20218
20225
202311
20247
20257
20266

Who runs them

Industry 51 · Other 170

AstraZeneca (41) · M.D. Anderson Cancer Center (10) · MedImmune LLC (8) · Canadian Cancer Trials Group (8) · Memorial Sloan Kettering Cancer Center (7) · National Cancer Institute (NCI) (5) · Jonsson Comprehensive Cancer Center (4) · Seoul National University Hospital (4)

Often tested with

Tested in the same studies.

Durvalumab (122) · Durvalumab/Tremelimumab Regimen (6) · Cisplatin (6) · Carboplatin (5) · Olaparib (5) · Bevacizumab (4) · Paclitaxel (4) · Lenvatinib (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Tremelimumab is the comparator. A study of two new drugs counts under both.

New treatments tested with it · 8 most studied

New when their studies opened, with tremelimumab beside them; studies of each.

Reaching primary completion within a year · 24, 2 in phase 3

Studies that test tremelimumab, phase 3 first.

Studies

Open first, then newest update. How each study uses tremelimumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 221

See all 221 studies that test tremelimumab →

Behind its US label · 2 — the studies the FDA label of IMJUDO describes

From the Clinical Studies section of IMJUDO (2026-08), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 11 — no other medicine in its arm
Tested with established drugs · 66 — they are given beside it

Showing 20 of 66. See all 66 →

Tested in a combination · 143 — another drug in the study is under test too

Showing 20 of 143. See all 143 →

Beside an established treatment under test · 16 — an approved drug, surgery or radiation is what the study tests

Tested with tremelimumab: Radiation 5 · Surgery or a procedure 2 · belinostat 1 · Cyclophosphamide 1 · Capecitabine 1 · Durvalumab/Tremelimumab Regimen 1 · Semaglutide 1 · Systemic Therapy 1

Beside a new treatment under test · 23 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with tremelimumab: durvalumab 3 · zanzalintinib 2 · nelitolimod 1 · danvatirsen 1 · azd-5069 1 · feladilimab 1 · JX-594 1 · MEDI3617 1

Showing 20 of 23. See all 23 →

As the comparator · 1 — what is tested is compared with tremelimumab
Observed · 15 — patients on it are followed, or it is given outside a trial

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call tremelimumab · ClinicalTrials.gg INT005105

  • MeSH (NLM) C520704tremelimumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) QEN1X95CIXTREMELIMUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2619313One source FDA
  • Wikidata Q7838098tremelimumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C49085TremelimumabOne source FDA
  • DrugBank DB11771One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion